anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To find out a material having action for promoting laminin 5 production out of natural products and provide an agent promoting the laminin 5 production, an agent normalizing dermal basement membranes and an agent promoting recovery of skin lesion, containing the same as an active ingredient.  <P>SOLUTION: The agent promoting the laminin 5 production, the agent normalizing dermal basement membranes and the agent promoting recovery of skin lesion comprise one or more kinds of extracts selected from the group consisting of Sasa veitchii RERD. extracts, Angelica keiskei Koidzumi extracts, Royal jelly extracts, Tilia cordata Mill. or Tilia platyphyllos Scop. extracts, Rubus ellipticus extracts, Asparagus officinalis extracts, Lonicera japonica Thunberg extracts, Houttuynia cordata Thunberg extracts, Lentinula edodes (Berk.) Pegler or Cortinellus shiitake, P. Henn. extract, Sanguisorba officinalis L. extracts, Foeniculum vulgare Miller extracts and Zizyphus jujuba Miller var. inermis extracts as active ingredients.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to an innate immunity-enhancing and anti-viral pharmaceutical composition comprising an extract of Hovenia dulcis Thunb. as an active ingredient, an innate immunity-enhancing and anti-viral health-aid food comprising an extract of Hovenia dulcis Thunb. as an active ingredient, and an innate immunity-enhancing and anti-viral feed composition comprising an extract of Hovenia dulcis Thunb. as an active ingredient. The present invention also relates to a method for enhancing innate immunity and anti-viral activities of animals, which comprises administering an extract of Hovenia dulcis Thunb. to non-human animals in need thereof. The innate immunity-enhancing and anti-viral pharmaceutical composition comprising an extract of Hovenia dulcis Thunb. according to the present invention shows an anti-viral activity and an effect enhancing innate immunity. Thus, the composition can be used for preventing and treating bacterial and viral infection diseases, and can be utilized widely for a pharmaceutical or health-aid food for enhancing and controlling immunity of an immuno-depressed or immuno-suppressed patient and for an innate immunity-enhancing and anti-viral feed for reinforcing the resistance of an animal against diseases. In addition, the innate immunity-enhancing and anti-viral composition according to the present invention causes little toxicity and side-effect, and thus can be used safely for a long administration period for the purpose of prevention.
Shortly after the discovery of Klotho, interest grew in its potential role in chronic kidney disease (CKD). There are three isoforms of the Klotho protein: αKlotho, βKlotho and γKlotho. This review will focus on αKlotho due to its relevance as a biomarker in CKD. αKlotho is synthesized mainly in the kidneys, but it can be released into the bloodstream and urine as soluble Klotho (sKlotho), which undertakes systemic actions, independently or in combination with FGF23. It is usually accepted that sKlotho levels are reduced early in CKD and that lower levels of sKlotho might be associated with the main chronic kidney disease-mineral bone disorders (CKD-MBDs): cardiovascular and bone disease. However, as results are inconsistent, the applicability of sKlotho as a CKD-MBD biomarker is still a matter of controversy. Much of the inconsistency can be explained due to low sample numbers, the low quality of clinical studies, the lack of standardized assays to assess sKlotho and a lack of consensus on sample processing, especially in urine. In recent decades, because of our longer life expectancies, the prevalence of accelerated-ageing diseases, such as CKD, has increased. Exercise, social interaction and caloric restriction are considered key factors for healthy ageing. While exercise and social interaction seem to be related to higher serum sKlotho levels, it is not clear whether serum sKlotho might be influenced by caloric restriction. This review focuses on the possible role of sKlotho as a biomarker in CKD-MBD, highlighting the difference between solid knowledge and areas requiring further research, including the role of sKlotho in healthy ageing.
BACKGROUND: JinLiDa granules (JLD) is a traditional Chinese medicine (TCM) used to treat type 2 diabetes mellitus with Qi and Yin deficiency. Clinical evidence has shown that JLD can alleviate diabetic cardiomyopathy, but the exact mechanism is not yet clear.
PURPOSE: The purpose of this study was to examine the potential role and mechanism of JLD in the treatment of diabetic cardiomyopathy through network pharmacological analysis and basic experiments.
METHODS: The targets of JLD associated with diabetic cardiomyopathy were examined by network pharmacology. Protein interaction analysis was performed on the targets, and the associated pathways were searched by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Diabetic mice were treated with low or high doses of JLD by gavage, and AC16 and H9C2 cardiomyocytes exposed to high-glucose conditions were treated with JLD. The analysis results were verified by various experimental techniques to examine molecular mechanisms.
RESULTS: Network pharmacological analysis revealed that JLD acted on the tumor suppressor p53 (TP53) during inflammation and fibrosis associated with diabetic cardiomyopathy. The results of basic experiments showed that after JLD treatment, ventricular wall thickening in diabetic mouse hearts was attenuated, cardiac hypertrophy and myocardial inflammation were alleviated, and the expression of cardiac hypertrophy- and inflammation-related factors in cardiomyocytes exposed to a high-glucose environment was decreased. Cardiomyocyte morphology also improved after JLD treatment. TP53 expression and the tumor necrosis factor (TNF) and transforming growth factor beta-1 (TGFβ1) signaling pathways were significantly altered, and inhibiting TP53 expression effectively alleviated the activation of the TNF and TGFβ1 signaling pathways under high glucose conditions. Overexpression of TP53 activated these signaling pathways.
CONCLUSIONS: JLD acted on TP53 to regulate the TNF and TGFβ1 signaling pathways, effectively alleviating cardiomyocyte hypertrophy and inflammation in high glucose and diabetic conditions. Our study provides a solid foundation for the future treatment of diabetic cardiomyopathy with JLD.
Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder impacting various organs, notably prevalent in women of reproductive age. This review explores the involvement of a disintegrin and metalloproteinases (ADAMs) in SLE pathogenesis. Despite advancements in understanding SLE through genome and transcriptome studies, the role of ADAMs in post-translational regulations remains insufficiently explored. ADAMs, transmembrane proteins with diverse functions, impact cell adhesion, migration, and inflammation by shedding cell surface proteins, growth factors, and receptors. Notably, ADAM9 is implicated in Th17 cell differentiation, which is crucial in SLE pathology. ADAM10 and ADAM17 play pivotal roles in T-cell biology, influencing immune cell development and differentiation. Elevated soluble ADAM substrates in SLE patients serve as potential biomarkers correlating with disease activity. Targeting ADAMs or their substrates offers promising therapeutic avenues for SLE management and treatment enhancement.
INTRODUCTION: Pulmonary hypertension (PHTN) is associated with increased morbidity and mortality in noncardiac surgery and elective surgery. This population of patients has a low physiological reserve and is prone to cardiac arrest as a result. This study aims to identify the impact that PHTN has on outcomes among geriatric hip fracture patients.
METHODS: A 3:1 propensity-score-matched retrospective case (PHTN)-control (no PHTN [N]) study of hip fracture patients from 2014 to 2022 was performed. Patients were matched utilizing propensity score matching of a validated geriatric trauma risk assessment tool (STTGMA). All patients were reviewed for hospital quality measures and outcomes. Comparative univariable and multivariable analyses were conducted between the two matched cohorts. A sub-analysis compared patients across PHTN severity levels (mild, moderate, severe) based on pulmonary artery systolic pressures (PASP) as measured by transthoracic echocardiogram.
RESULTS: PHTN patients (n = 67) experienced a higher rate of inpatient, 30-day, and 1-year mortality, major complications, and 90-day readmissions as compared to the N cohort (n = 201). PHTN patients with a PASP > 60 experienced a significantly higher rate of major complications, need for ICU, longer admission length, and worse 1-year functional outcomes. Pulmonary hypertension was found to be independently associated with a 3.5 × higher rate of 30-day mortality (p = 0.016), 2.7 × higher rate of 1-year mortality (p = 0.008), 2.5 × higher rate of a major inpatient complication (p = 0.028), and 1.2 × higher rate of 90-day readmission (p = 0.044).
CONCLUSION: Patients who had a prior diagnosis of pulmonary hypertension before sustaining their hip fracture experienced significantly worse inpatient and post-discharge outcomes. Those with a PASP > 60 mmHg had worse outcomes within the PHTN cohort. Providers must recognize these at-risk patients at the time of arrival to adjust care planning accordingly.
LEVEL OF EVIDENCE: III.
Increasing evidence suggests that rTMS has been effective in treating various psychological and neurological diseases, including treating post-stroke symptoms. Using the personalized brain functional sectors (pBFS) technique, investigators could precisely identify individualized brain functional networks and the personalized language-related stimulation site based on the resting-state functional MRI data. The current study proposes to conduct a double-blinded, randomized and parallel controlled design trial, to investigate the efficacy and safety of pBFS-guided personalized rTMS intervention in post-stroke aphasic patients.

Subjects will be randomly assigned to the following six groups: active 1200-pulse cTBS group, active 2400-pulse cTBS group, active 3600-pulse cTBS group, sham 1200-pulse cTBS group, sham 2400-pulse cTBS group, or sham 3600-pulse cTBS group. The allocation ratio will be 3:3:3:1:1:1. The stimulation protocol consisted of a 3-week treatment, with 5 consecutive workdays each week (totally 15 day-treatment). The stimulation procedure will be assisted with real-time neuronavigation to ensure its precision.
Plasmodium falciparum (Pf) malaria remains responsible for an intolerable burden of morbidity worldwide and an effective vaccine is sorely needed to aid control efforts. Before candidate malaria vaccines can enter full-scale (phase IIb) field trials in endemic areas, they must first be tested under controlled circumstances in (phase IIa) clinical human malaria infection studies. Since Pf isolates display a wide genetic diversity across the globe, phase IIa challenge infections should be conducted with both homologous and heterologous strains.

Since 1998 a highly successful Controlled Human Malaria Infection model at the UMC St Radboud, Nijmegen, The Netherlands, has been employed both to test candidate vaccines and to answer fundamental questions about pathophysiological and immunological mechanisms during early Pf infection in human volunteers. To date largely the NF54 strain of P. falciparum has been used in this Nijmegen model, with which extensive experience has meanwhile been acquired. In order to increase the portfolio of Pf strains available for future phase IIa studies, it is first necessary to document in detail the parasitological, clinical and immunological characteristics of new candidate strains during a controlled human malaria infection. In this study, the strains NF135 and NF166 will be compared in this regard with the well-characterised NF54 strain.
Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
OBJECTIVES: The purpose of this study was to evaluate the risk of pesticide poisoning, liver and renal failure, dermatitis, respiratory problems, hypersensitivity pneumonitis, keratitis, and epilepsy among pesticide-spraying personnel and to assess the effectiveness of a new method of aerial pesticide application in reducing this risk.
METHODS: A total of 2268 pesticide spraying operators (1651 ground-based field crop operators and 617 aerial pesticide spraying drone operators) who passed the national certification examination between 2010 and 2020 in Taiwan were included. Ground-based operators served as the positive control group, while 2463 farmer controls were matched from the Farmers' Health Insurance database as the negative control group. Data from the National Health Insurance Research Database were used to track possible pesticide-related disease cases. Logistic regression was employed to calculate odds ratios and 95% confidence intervals (95% CI).
RESULTS: Drone operators had significantly reduced risks of dermatitis, asthma and chronic bronchitis compared to ground-based operators. This was observed in allergic contact dermatitis (OR = 0.40, 95% CI: 0.24-0.68), unspecified contact dermatitis (OR = 0.58, 95% CI: 0.35-0.97), asthma (OR = 0.27, 95% CI: 0.12-0.60), and chronic bronchitis (OR = 0.24, 95% CI: 0.06-0.93), after adjusting for age, sex, working areas, and licensing years. However, no significant differences were found when comparing drone operators to matching farmers.
CONCLUSIONS: Aerial pesticide spraying using drones may contribute to a decreased risk of dermatitis, asthma and chronic bronchitis, suggesting potential health benefits for operators. Further field pesticide exposure surveys are recommended to validate these findings and assess health risk indicators.
The invention relates to a formula of a medicinal liquor. Generally speaking, hemorrhoid treatment needs both of external medicines and inner adjustment to make hemorrhoid slowly better. Present specialized medicines for hemorrhoid treatment mainly comprises Enfnis at abroad, and Mayinglong Ruangao in China, wherein Enfnis is known for the substantial hemorrhoid curative effect and has a high price, and Mayinglong Ruangao which has a certain effect to alleviate hemorrhoid cannot fundamentally control hemorrhoid, but can temporarily alleviate aches. An operative therapy for hemorrhoid treatment is to remove haemorrhoids, there is a little pain in the operation and after the operation, and requirements on operation conditions are high. Other therapies comprise a medicine injection therapy, a necrosis therapy of haemorrhoids, an infrared therapy, a frigotherapy, a laser therapy, and the like. The medicinal liquor which adopts Chinese herbal medicines mainly aims at hemorrhoid patients, and especially has an obvious curative effect on internal hemorrhoid. The medicinal liquor has the characteristics of simplicity, easy usage, low cost, and obvious effect.
Methods and compositions are disclosed for producing air-activated, i.e., oxygen (O2) activated, disinfectant-sterilent solutions. Solutions containing a haloperoxidase (i.e., a halide:hydrogen peroxide (H2O2) oxidoreductase, such as myeloperoxidase, eosinophil peroxidase or lactoperoxidase) plus a halide or combination of halides (i.e., chloride, bromide and/or iodide), an oxidase (i.e., a substrate: O2 oxidoreductase) capable of generating H2O2, and a substrate specific for that oxidase, are separately prepared under aerobic conditions, but all of the component solutions are made anaerobic prior to final combination and mixing. The anaerobic formulations are dispensed into containers capable of maintaining the anaerobic condition (e.g., pressurized canisters). Dispensing the solution at the time of use exposes the formulation to air (i.e., O2) which activates its disinfectant-sterilent properties. O2 is the rate limiting component for oxidase generation of H2O2. Under aerobic conditions the oxidase catalyzes the oxidation of its substrate and the reduction of O2 to generate H2O2. In turn, H2O2 serves as substrate for haloperoxidase which catalyzes the oxidation of halide to hypohalous acid. Hypohalous acid reacts with an additional H2O2 to generate singlet molecular oxygen (1O2). Hypohalous acid (e.g., hypochlorous acid) and especially 1O2 are potent microbicidal agents. Both haloperoxidase generation of hypohalous acid and its reactive consumption to yield 1O2 are dependent on the availability of H2O2. A high rate of H2O2 generation does not result in the accumulation of hypohalous acid, but instead results in a high rate of 1O2 production. The microbicidal capacity and toxicity of 1O2 are limited by the half-life of this metastable electronically excited reactant, and as such, disinfectant-sterilent activity is temporally defined by and confined to the dynamics of oxidant generation.
The invention discloses a mental disorder biomarker and application thereof. Microorganism gene chip hybridization research is conducted on intestinal flora microbial genomes in fecal samples of a mental disorder group and fecal samples of a healthy control group to describe characteristics of fecal microflorae and functional genes. By means of difference testing, discriminant analysis and machine learning, fifteen functional genes are recognized finally and can serve as biomarkers to highly accurately distinguish the mental disorder group. The biomarker is selected from at least ten genes in the fifteen functional genes. The fifteen functional genes have obvious differences in mental disorder people and the healthy people. The invention further discloses a drug which is capable of changing the number or expression of genes and is used for treating mental disorder, a method for producing or screening the drug for treating mental disorder and a kit for detecting mental disorder.
The present invention is based on the discovery of a novel human virus that has been designated as a Cryptovirus, which falls within the Rubulavirus genus of the Paramyxoviridae. Disclosed are isolated Cryptovirus-specific nucleic acids, nucleic acid constructs containing the Cryptovirus-specific nucleic acids, Cryptovirus-specific proteins, isolatedCryptovirus particles, isolated anti-Cryptovirus antibodies, and compositions containing them. Uses for manufacturing a vaccine or a medicament are also disclosed. Also disclosed are inventive vectors containing the Cryptovirus-specific nucleic acids and host cells containing the vectors. Methods if isolating and propagating Cryptovirus are disclosed, as are methods of producing a mammalian cell line acutely or non productively infected with Cryptovirus; such cells are disclosed.  Disclosed also are methods of detecting Cryptovirus particles, proteins or anti-Cryptovirus antibodies in a sample of a biological material. In vitro and in vivo screening methods for identifying potential antiviral therapeutic or prophylactic agents are disclosed. Methods of detecting a Cryptovirus infection in a mammal are disclosed. Methods of detecting Cryptovirus infection in a mammal are disclosed. Also disclosed is an animal model for human diseases, such as neurological, neurodegenerative, and/or neuropsychiatric diseases, including epileptiform diseases (e.g., epilepsy, multiple sclerosis, chronic fatigue syndrome, and subacute sclerosing panencephalitis).
SCOPE: Tolypocladium sinense is a fungus isolated from Cordyceps. Cordyceps has some medicinal value and is also a daily health care product. This study explores the preventive effects of T. sinense mycelium polysaccharide (TSMP) on high-fat diet-induced obesity and chronic inflammation in mice.
METHODS AND RESULTS: Here, the study establishes an obese mouse model induced by high-fat diet. In this study, the mice are administered TSMP daily basis to evaluate its effect on alleviating obesity. The results show that TSMP can significantly inhibit obesity and alleviate dyslipidemia by regulating the expression of lipid metabolism-related genes such as liver kinase B1 (LKB1), phosphorylated AMP-activated protein kinase (pAMPK), peroxisome proliferator activated receptor α (PPARα), fatty acid synthase (FAS), and hydroxymethylglutaryl-CoA reductase (HMGCR) in the liver. TSMP can increase the protein expression of zona occludens-1 (ZO-1), Occludin, and Claudin-1 in the colon, improve the intestinal barrier dysfunction, and reduce the level of serum LPS, thereby reducing the inflammatory response. 16S rDNA sequencing shows that TSMP alters the intestinal microbiota by increasing the relative abundance of Akkermansia, Lactobacillus, and Prevotellaceae_NK3B31_group, while decreasing the relative abundance of Faecalibaculum.
CONCLUSION: The findings show that TSMP can inhibit obesity and alleviates obesity-related lipid metabolism disorders, inflammatory responses, and oxidative stress by modulating the gut microbiota and improving intestinal barrier.
The present invention relates to a method for simultaneously producing a hepatitis A virus antigen and a hepatitis E virus antigen, and a hepatitis preventing vaccine and a diagnosing kit containing produced antigens. In particular, the present invention relates to: a method for simultaneously producing a part of a VP1 protein as a hepatitis A virus antigen and a part of an ORF2 protein as a hepatitis E virus antigen from an insect cell; a preventing vaccine for inducing generation of antigens for two viruses by containing produced antigens; and a diagnosing kit for detecting antibodies for two viruses existing in a subject by containing the antigens. According to the present invention, a hepatitis A virus antigen and a hepatitis E virus antigen can be simultaneously and stably produced. Moreover, produced antigens can be usefully used as a vaccine for simultaneously preventing infection of the two viruses, or as a kit for diagnosing infection. The viruses can be infected from livestock, so when the vaccine and kit of the present invention are used to manage livestock, a virus retaining possibility can be blocked. Accordingly, it is determined that transition to a human can be prevented in advance. Simultaneous infection causing sever hepatitis can also be prevented, so the present invention is expected to remarkably help to control diseases.
Clinical decision support systems employing reverse phenotyping. In various embodiments, genomic information of a patient is read from a datastore. One or more variant of the genomic information is determined. The one or more variant is associated with a disease state. One or more phenotypic features are determined, associated with the one or more variant. A healthcare provider is prompted to evaluate the patient for the one or more phenotypic features.